![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Under the agreement, ProgenaCare will commercialize coactiv+ (disodium EDTA) Antimicrobial Wound Gel in the U.S. wound care market. The coactiv+ is a combination of Kane’s patented coactiv+™ technology and PHMB, paired with a non-ionic pluronic surfactant.
Lead Product(s): Edetate Calcium Disodium,Sodium Citrate
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Coactiv+
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kane Biotech
Deal Size: Undisclosed Upfront Cash: $0.5 million
Deal Type: Agreement April 20, 2023
Details:
The coactiv+™ (disodium EDTA) Antimicrobial Hydrogel is a combination of Kane’s patented coactiv+™ antibiofilm technology and PHMB in a thermo-reversible gel.
Lead Product(s): Edetate Calcium Disodium,Sodium Citrate
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Coactiv+
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Salud Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 04, 2023